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ABSTRACT
Repeat tumor biopsies to study genomic changes during therapy are difficult, 
invasive and data are confounded by tumoral heterogeneity. The analysis of circulating 
tumor DNA (ctDNA) can provide a non-invasive approach to assess prognosis and 
the genetic evolution of tumors in response to therapy. Mutation-specific droplet 
digital PCR was used to measure plasma concentrations of oncogenic BRAF and NRAS 
variants in 48 patients with advanced metastatic melanoma prior to treatment with 
targeted therapies (vemurafenib, dabrafenib or dabrafenib/trametinib combination) 
or immunotherapies (ipilimumab, nivolumab or pembrolizumab). Baseline ctDNA levels 
were evaluated relative to treatment response and progression-free survival (PFS). 
Tumor-associated ctDNA was detected in the plasma of 35/48 (73%) patients prior 
to treatment and lower ctDNA levels at this time point were significantly associated 
with response to treatment and prolonged PFS, irrespective of therapy type.  Levels of 
ctDNA decreased significantly in patients treated with MAPK inhibitors (p < 0.001) in 
accordance with response to therapy, but this was not apparent in patients receiving 
immunotherapies. We show that circulating NRAS mutations, known to confer 
resistance to BRAF inhibitors, were detected in 3 of 7 (43%) patients progressing on 
kinase inhibitor therapy. Significantly, ctDNA rebound and circulating mutant NRAS 
preceded radiological detection of progressive disease. Our data demonstrate that 
ctDNA is a useful biomarker of response to kinase inhibitor therapy and can be used 
to monitor tumor evolution and detect the early appearance of resistance effectors.
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INTRODUCTION
Most melanomas display aberrant activation of 
the mitogen activated protein kinase (MAPK) pathway 
[1], most frequently via oncogenic mutations affecting 
BRAF and NRAS [2]. BRAF mutations commonly result 
in the substitution of the valine at codon 600 for glutamic 
acid (V600E; 80%), lysine (V600K; 12%), methionine, 
arginine or aspartic acid (each 4-5%) [3-6]. BRAFV600-
mutant melanomas are exquisitely sensitive to BRAF 
inhibitors such as dabrafenib and vemurafenib, which 
alone or in combination with a MEK inhibitor improve the 
overall survival of BRAFV600-mutant melanoma patients 
[7-10]. Despite these therapeutic advances approximately 
50% of melanoma patients treated with BRAF and MEK 
inhibitors will progress within 12 months. Resistance 
usually involves MAPK reactivation, often via mutations 
affecting NRAS or MEK, mutant BRAF gene amplifications 
or alternative BRAF splicing [11-13]. Acquired resistance 
mechanisms differ between and within patients and also 
exhibit intra-tumoral heterogeneity [11, 12]. 
In addition to targeted therapies, recent clinical 
trials have demonstrated the efficacy of reactivating anti-
tumor immune responses by targeting inhibitory immune 
receptors. Monoclonal antibodies against the CTLA-4 
receptor (ipilimumab) and the PD-1 receptor (nivolumab 
and pembrolizumab) show remarkable long-term benefits 
in the 10% and 40% of patients who respond, respectively 
[14-17]. These immunotherapies show delayed activity, 
and tumor regression can occur after initial tumor 
enlargement [18, 19]. Altogether the above underscores 
the need for better prognostic markers and early indicators 
of response to treatment.
The analysis of circulating tumor DNA (ctDNA) can 
provide valuable prognostic information and reveal tumor 
genetic changes, including the acquisition of resistance-
conferring mutations during therapy in a variety of cancers 
[20-24]. In melanoma, the quantity of tumor associated 
mutant BRAF ctDNA correlated with tumor burden, and 
lower concentrations of basal mutant BRAF ctDNA were 
associated with a higher overall response rate and longer 
progression-free survival (PFS) in patients treated with 
BRAF inhibitors [25, 26]. More recently, Lipson et al. 
showed that levels of ctDNA correlated with radiological 
outcomes in a small group of melanoma patients treated 
with immunotherapies [27]. Similarly Tsao et al. showed 
changes in ctDNA levels in six patients treated with 
different immunotherapy modalities that reflected changes 
in their disease status [28]. 
In this study we analysed the ctDNA in BRAF 
and NRAS-mutated melanoma patients at baseline (n = 
48) and within 8 weeks of treatment initiation (n = 25) 
to determine whether ctDNA correlates with treatment 
response and clinical benefit. We also analysed the 
dynamic changes in ctDNA in response to MAPK 
inhibitors and immunotherapies during response and after 
progression. Furthermore, we evaluated the ctDNA for the 
presence of mutations associated with resistance to BRAF 
inhibitor therapy. 
RESULTS
Baseline ctDNA levels are associated with 
treatment response and PFS
We quantified the amount of ctDNA in 48 patient 
plasma samples collected at baseline, i.e. 0-2 weeks prior 
to treatment initiation. ctDNA was detectable in 22 of 
34 cases (65%) with BRAFV600E tumors (one requiring a 
different probe as the patient carried a 1799-1800 TG > 
AA mutation), in 7 out of 8 patients with BRAFV600K and in 
all cases with BRAFV600R (n = 2) and NRASQ61K/R/L (n = 4) 
tumors. Detectable ctDNA levels ranged from 1.6-57,302 
copies/ml. Interestingly a significant correlation was found 
between the concentration of ctDNA and plasma LDH 
activity (n = 26, r = 0.76, p < 0.0001) (Supplementary 
Figure 1). 
Of the 48 cases analysed in this study, 29 were 
treated with MAPK inhibiting therapies (24 dabrafenib/
trametinib, 4 vemurafenib and 1 dabrafenib monotherapy) 
while 19 were treated with immunotherapies (9 with 
ipilimumab, 3 with nivolumab, 6 with pembrolizumab 
and 1 with a combination of ipilimumab/pembrolizumab). 
Patients that responded to targeted therapy had 
significantly lower baseline ctDNA than non-responders 
(median, 10.5 versus 1695 copies/ml, p = 0.042, Mann-
Whitney U-test) (Figure 1A). Of note, all cases with < 
10 copies/ml of ctDNA at baseline (n = 12) responded 
to therapy. However this association was not statistically 
significant possibly due to the limited number of non-
responders. Patients receiving immunotherapy that 
responded to treatment also had significantly lower 
baseline ctDNA than non-responders (median, 5 versus 
87.2 copies/ml, p = 0.049, Mann-Whitney U-test) (Figure 
1B). Moreover, baseline ctDNA ( < 10 copies/ml) was 
significantly associated with response to immunotherapy 
(p = 0.009, Relative risk 5, 95% CI 1.8-13.8). 
Similarly, targeted therapy treated patients with 
PFS longer than 6 months had significantly lower median 
baseline concentrations of ctDNA compared to those 
with PFS less than 6 months (1 versus 725 copies/ml, p = 
0.008, Mann-Whitney U-test) (Figure 1C). Low baseline 
ctDNA levels were associated with longer than 6 month 
PFS (p = 0.0057, RR = 1.9, 95% CI 1.2-2.9). Patients 
receiving immunotherapy with PFS longer than 6 months 
also had significantly lower baseline ctDNA compared 
to those with less than 6 months PFS (median, 5 versus 
87.2 copies/ml, p = 0.049, Mann-Whitney U-test) (Figure 
1D). Moreover, baseline ctDNA ( < 10 copies/ml) was 
significantly associated with 6 months PFS (p = 0.009, 
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Figure 1: Baseline ctDNA association with response to treatment and PFS. Association of baseline ctDNA concentrations with 
A. and B. response to treatment and C. and D. 6 months PFS. Median with interquartile range is indicated on each data set. Contingency 
tables with corresponding Fisher’s exact test p-value are indicated below each graph. Kaplan-Meier plots of PFS probabilities according 
to baseline ctDNA concentrations of E. cases treated with targeted therapies (n = 29) and F. immunotherapies (n = 19). Cox regression 
p-values, Hazard ratio (HR) and confidence intervals are indicated for each plot.
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Relative risk 5, 95% CI 1.8-13.8). 
In a Cox regression analysis, patients on targeted 
therapy with ≥10 copies/ml of ctDNA at baseline had a 
significantly shorter PFS compared to patients that had 
< 10 copies/ml of ctDNA (p = 0.008, Hazard ratio = 
4.6, 95% CI, 1.5-14.1) (Figure 1E). A multivariate Cox 
regression analysis revealed that the predictive value of 
low baseline ctDNA on longer PFS in patients treated 
with MAPK inhibitors remained significant (p = 0.027) 
and independent of sex, age, tumor stage or LDH levels 
(Table 1). Low ctDNA levels ( < 10 copies/ml) were also 
statistically significant associated with longer PFS for 
patients treated with immunotherapies (p = 0.034, Hazard 
ratio = 3.7, 95% CI 1.2-12.5) (Figure 1F).
Overall these results suggest that low baseline 
ctDNA is a good predictor of response to treatment and 
longer PFS. Notably, of the 32 cases with high baseline 
ctDNA levels, 17 responded to therapy and 12 had a 
PFS longer than 6 months, suggesting that low baseline 
ctDNA ( < 10 copies/ml) is predictive, but not an absolute 
indicator of treatment outcome and clinical benefit.
Decrease in ctDNA after therapy initiation
A subgroup of 25 patients (10 on MAPKi and 15 on 
immunotherapy) with detectable ctDNA at baseline was 
also sampled between 4 to 8 weeks after therapy initiation. 
The concentration of plasma ctDNA significantly 
decreased in most patients after therapy initiation 
compared to baseline concentrations. This decrease (which 
ranged from 100-1000 fold reduction) was more apparent 
amongst patients treated with and responding to MAPK 
inhibitors (p = 0.0071) (Figure 2A). By contrast, there 
was no apparent decrease in ctDNA, within a similar time 
frame, in most patients receiving immunotherapies (Figure 
2C and 2D). Of note, only 4 of the 15 immunotherapy-
treated patients analysed in this subgroup, responded to 
treatment (Figure 2C). A 10-fold reduction in ctDNA was 
observed in 2 of these 4 responders, while the other 2 had 
a low baseline ctDNA concentration, and this remained 
low, but detectable, 6 weeks later. 
Two patients (one treated with vemurafenib and one 
with nivolumab) defined as non-responders, also had a 10-
fold reduction in ctDNA levels (marked with asterisks in 
Figure 2B and 2D). Both of them had prolonged stable 
disease for greater than 6 months, suggesting that the 
treatment had some effect on tumor activity, reflected in 
the decreasing ctDNA levels. One of these patients was 
treated with nivolumab and had evidence of progressive 
disease at first scan. The patient received second modality 
treatment with radiotherapy to an enlarging chest wall 
lesion and continued treatment with anti-PD-1 antibody. 
He achieved ongoing disease control for greater than 
6 months. This atypical pattern of response has been 
described in 4% of patients in the early nivolumab trials, 
where subsequent response is observed after having 
progressive disease (PD) on initial assessment [29, 30]. 
Changes in ctDNA levels in melanoma patients 
during therapy and at progression
We monitored ctDNA level in four patients, treated 
with dabrafenib/trametinib as first line therapy (Figure 3 
A-3D). In all four patients a dramatic decline in ctDNA 
concentrations was recorded within 1-3 weeks after 
commencing treatment, decreasing to undetectable levels 
in 3 patients by 6 weeks. However, ctDNA rebounded in 
all cases prior to, or at the time of, detection of progressive 
disease by CT scans. In particular, in patient #17 (Figure 
3B) a clear recurrence of tumor burden was apparent by 
ctDNA analysis at 30 weeks after treatment initiation, 
however the radiological analysis classified the disease 
status as stable at that time with progression only noted at 
39 weeks. All four patients were treated with ipilimumab 
after failing the MAPK inhibitor therapy, but none 
responded to immunotherapy. The presence of ctDNA 
remained detectable during and after immunotherapy.
Of note, a patient that experienced complete 
response to treatment (Figure 3E), developed a solitary 
brain metastasis of 18 millimetres at week 22, but ctDNA 
rebound was not detected in plasma sampled prior to 
Table 1: Factors associated with PFS in patients treated with targeted therapies 
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stereotactic radiosurgery at week 27. This observation 
may question the utility of ctDNA quantification in the 
case of brain metastases, consistent with previous studies 
suggesting that the blood-brain barrier may prevent ctDNA 
from entering the circulation [20]. 
Detection of acquired resistance mutations in 
ctDNA
Mutations in NRAS have been found in 8-26% of 
patients with acquired resistance to BRAF inhibitors [11, 
13]. We analysed the presence of NRASQ61K and NRASQ61R 
in the ctDNA extracted from 7 melanoma patients with 
progressive disease who had previously responded 
to treatment with vemurafenib (n = 2) or dabrafenib/
trametinib (n = 5). Two samples were positive for 
NRASQ61K and one sample had an NRASQ61R mutation, all 
three were derived from patients treated with dabrafenib/
trametinib.
For all three positive cases the presence of NRAS 
mutations was evaluated in longitudinally collected 
samples (Figure 3B-3D, Supplementary Figure 2). No 
mutated NRAS was detectable prior to treatment initiation 
(baseline) or prior to ctDNA rebound. The amount of 
mutant NRAS ctDNA increased as the BRAF mutant 
ctDNA rebounded and both fluctuated in a similar pattern. 
However, mutant NRAS ctDNA was consistently detected 
at lower quantities than BRAF mutant ctDNA. Of note, 
in patient #17 the escape mutation NRASQ61K could be 
detected from week 20, however no progressive disease 
was apparent by radiological scan at week 30 (Figure 
3B), once again supporting the value of ctDNA analysis 
for monitoring melanoma patients undergoing systemic 
therapies.
DISCUSSION
Our results demonstrate that quantification of plasma 
ctDNA is a valuable tool for monitoring tumor dynamics 
in metastatic melanoma patients. The quantity of ctDNA 
in plasma tracks the patient’s response to treatment and 
precedes radiological disease progression. Moreover we 
demonstrate, for the first time, that mutations conferring 
resistance to BRAF and MEK inhibitors can be detected in 
the ctDNA of patients undergoing targeted therapies, prior 
to radiological evidence of progression. 
Due to logistics of sample collection and transport, 
plasma samples used in the study were derived from 
blood processed 16-24 hours after collection. Although 
most protocols for the analysis of ctDNA recommend 
plasma separation within 2-4 hours [31], the agreement 
of our ctDNA quantities with clinical status indicated that 
Figure 2: Change in ctDNA levels after therapy initiation relative to baseline. Plasma samples were tested for ctDNA at 
baseline and between 4 to 8 weeks after therapy initiation (follow up). Cases are colour coded according to therapy, and grouped by therapy 
type and response. * indicates two patients that were classified as non-responders but had stable disease for at least 6 months.
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Figure 3: Monitoring ctDNA in plasma during clinical disease course. Levels of BRAF and NRAS mutated ctDNA in plasma 
collected longitudinally from five melanoma patients during treatment with A.-D. dabrafenib and trametinib combination therapy, followed 
by immunotherapies and E. during ipilimumab treatment. Clinical outcomes revealed by CT and/or PET scans are indicated at each 
assessment time (arrows). Patient death is indicated by a red cross (†). A. PET scan images at four clinical assessment time points for 
comparison with ctDNA levels.
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the ctDNA was not compromised in these samples. We 
have also shown that plasma processing within 4 hours of 
blood collection did not significantly alter the amount of 
tumor associated ctDNA relative to processing at 24 hours 
(Supplementary Figure 3).
We found that low baseline ctDNA ( < 10 copies/
ml) was predictive of prolonged PFS compared to patients 
with a high baseline ctDNA, particularly in patients treated 
with targeted therapies, supporting previous reports [25, 
26]. Of note, the predictive value of ctDNA levels on PFS 
by Cox regression analyses remained significant at various 
cut-off values from 10-300 copies/ml (data not shown), 
including 216 copies/ml as described in a recent study by 
Sanmamed et al. [26]. However, all patients with baseline 
ctDNA < 10 copies per ml responded to therapy and had 
more than 6 month PFS, thus supporting 10 copies per 
ml as a biologically significant and data driven threshold, 
which was not apparent when 216 copies/ml was used as 
a classifier. Importantly, although a substantial proportion 
(14/17; 82%) of cases with > 10 ctDNA copies per ml 
responded to therapy, all rapidly progressing patients (PFS 
< 6 months) had high ctDNA ( > 10 copies/ml) at baseline. 
Significantly, we found that independent of baseline 
ctDNA levels, a decrease in ctDNA within 8 weeks after 
treatment initiation was associated with response to 
therapy. Thus, monitoring ctDNA early during therapy 
may provide long-term patient response information that 
can inform the timing for second line therapy initiation. 
Limitations of this study include the small sample 
size especially of patients treated with immune checkpoint 
inhibitors and the heterogeneity of the treatments given 
within this group which are known to have different modes 
of action and treatment response rates. Future studies are 
needed to evaluate the predictive value of baseline ctDNA 
in patients treated with particular immune checkpoint 
blockade modalities. Moreover, additional studies are 
required to evaluate the dynamic changes in ctDNA that 
provide early reliable prediction of treatment response. 
In particular it will be important to determine whether a 
decrease in ctDNA after initiation of immunotherapies 
provides a predictive measure of clinical benefit in patients 
with a delayed response.
Longitudinal analysis of ctDNA during treatment 
clearly demonstrated that ctDNA levels closely track 
clinical disease status. More importantly, a rebound 
in ctDNA levels correlated with treatment failure, and 
in at least one case preceded radiological detection of 
progressive disease. Future studies with more regular 
collection of plasma samples during therapy will confirm 
whether rebound of ctDNA generally precedes radiological 
detection of progression.
One of the most important findings of this study 
was the identification of acquired resistance via NRAS 
mutations in patients that initially responded to targeted 
therapy and subsequently progressed. To our knowledge 
this has not been previously reported for melanoma, 
and in the setting of tumor tissue heterogeneity, could 
identify the most important resistant clone to direct 
further treatment selection. For example in the LOGIC 2 
study (clinicaltrials.gov, NCT02159066) where patients 
are biopsied at progression and a second line treatment 
selected based on the genetic analysis of the biopsy, results 
can be confounded by inter- and intra-tumor heterogeneity. 
We show here that blood monitoring could be utilised 
to identify the most significant clone at resistance and 
confirm that it was not detectable at baseline.
Detection of acquired resistance mutations through 
ctDNA analysis has been previously demonstrated in 
colorectal cancer with the evolution of mutant KRAS to 
EGFR blockade [22]. Subsequent studies identified, by 
whole genome plasma DNA sequencing, the development 
of resistance to anti-EGFR therapies through KRAS 
amplification and polysomy of chromosome 12p [32, 
33]. Similarly, the resistance–conferring mutation EGFR 
T790M could be detected in plasma of lung cancer 
patients following treatment with gefitinib or erlotinib 
[24, 34]. Altogether these results underscore the utility of 
ctDNA analysis for non-invasive detection of treatment 
failure and the development of resistance.
The frequency of patients progressing on BRAF/
MEK inhibitors with NRAS mutations (43%) was larger 
than in any other studies, especially for treatment with 
dabrafenib/trametinib combination [30]. This could reflect 
the small number of patients analysed, but it is tempting 
to speculate that NRAS mutations were more commonly 
detected here because ctDNA is derived from the sum 
of a patient’s tumors. Previous studies profiling acquired 
resistance in melanoma, examined individual progressing 
lesions, which are known to display intra- and inter-
tumoral heterogeneity of resistance mechanisms [11, 12] 
[35]. Circulating mutant NRAS presumably originates from 
a subset of the melanoma burden, and this is supported by 
the fact that NRAS mutant ctDNA was consistently lower 
than the BRAF mutated ctDNA.
Overall these data confirm that measuring tumor-
associated ctDNA is a valuable and simple method to 
track patient response, tumor evolution and resistance 
acquisition. 
MATERIALS AND METHODS
Study design, patient cohorts and ethics statement
Metastatic melanoma patients were enrolled in the 
study between April 2013 and February 2015, based on 
having a confirmed BRAFV600E/K/R or NRASQ61R/K/L mutation 
in their melanoma by molecular analysis, at Sir Charles 
Gairdner Hospital (SCGH) and Fiona Stanley Hospital 
(FSH) in Perth, Western Australia, and Westmead 
Hospital and Melanoma Institute Australia, New South 
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Wales, Australia. Written informed consent was obtained 
from all patients under approved Human Research Ethics 
Committee protocols from Edith Cowan University (No. 
2932), Sir Charles Gairdner Hospital (No. 2007-123) and 
Royal Prince Alfred Hospital (Protocol No X10-0305 & 
HREC/10/RPAH/539).
Patient treatment and follow up
Patients were treated with either vemurafenib, 
dabrafenib/trametinib combination, ipilimumab, 
nivolumab, pembrolizumab or ipilimumab/pembrolizumab 
at the currently approved doses. Patients underwent 
baseline assessment including medical history, physical 
examination, and radiologic tumor assessment with 
computer tomography (CT) or positron emission 
tomography (PET) scans. Patients were treated at the 
discretion of their treating oncologist as appropriate 
for their disease stage, mutational status and Eastern 
Cooperative Oncology Group (ECOG) performance status. 
Patients underwent clinical assessment at least monthly, 
including a physical examination and assessment of 
biochemical parameters. Tumor responses were assessed 
radiologically at two to three month intervals. CT scans 
were assessed by RECIST 1.1 criteria [36] and classified 
as having a complete response (CR), partial response (PR), 
stable disease (SD) or progressive disease (PD). Patient 
information and samples collected are indicated in the 
Supplementary Table 1.
Plasma collection and cell free DNA extraction
Patient peripheral blood samples were collected 
in EDTA vacutainer tubes, stored at 4°C, and processed 
within 24 hours of being drawn. Blood samples were 
centrifuged at 1600g for 10 min for plasma collection, 
followed by a second centrifugation for further plasma 
clearance. Plasmas were stored at -80°C until extraction. 
The cell free DNA (cfDNA) was extracted from 1-5 ml 
of plasma using the QIAamp Circulating Nucleic Acid 
Kit (Qiagen) according to the manufacturer's instructions. 
cfDNA was eluted in AVE buffer (Qiagen). DNA samples 
were stored at -80 °C until analysis.
ctDNA quantification
The ctDNA was quantified by droplet digital PCR. 
Amplifications were carried out in a 20 µL reaction 
containing 1× droplet PCR supermix, 250 nM of each 
probe, 900 nM primers and 5 or 8 µL cfDNA. Samples 
were analysed for BRAF-V600E or V600K mutations 
depending on the mutation identified in the patient 
biopsy. The following probes were used: T1799-VIC 
WT (VIC-CTAGCTACAGTGAAATC-MGBNFQ) and 
A1799-FAM V600E (6FAM-TAGCTACAGAGAAATC-
MGBNFQ), AA1799-1800-FAM V600E2 
(6FAM- TAGCTACAGAAAAATC-MGBNFQ) 
or AA1798-1799-FAM V600K (6FAM-
TAGCTACAAAGAAATC-MGBNFQ). The following 
primers were used for both assays: 5’- CTACTGTTTTCC 
TTTACTTACTACTACACCTCAGA-3’ (forward) and 
5’-ATCCAGACAACTGTTCAAACTGATG-3’ (reverse). 
Probes and primers were custom synthesised by Life 
Technologies. NRAS mutations Q61K and Q61R were 
tested using the commercial PrimePCR mutation assays 
(BioRad).
Droplets were generated and analysed using the 
QX200 system (Bio-Rad). Amplifications were performed 
using the following conditions: 1 cycle of 95°C for 10 
minutes, 40 cycles of 94°C for 30 seconds and 55°C for 
1 minute, and 1 cycle of 98°C for 10 minutes. A positive 
control, a healthy control and a no template control were 
included in each run. QuantaSoft version 1.6.6 analysis 
software (Bio-Rad) was used for data acquisition and 
analysis. Only tests providing more than 10,000 droplets 
were used for analysis. The number of copies of mutated 
DNA per 20 µl reaction was extrapolated to calculate 
copies per ml using the following equation: 
Copies/ml of plasma = C*EV/TV/PV. 
PV = Volume of plasma used for cfDNA extraction 
(ml)
EV = Volume in which cfDNA was eluted (µl)
TV = Volume of cfDNA added to the PCR reaction 
(µl)
C = copies/20µl (data derived from QuantaSoft)
To facilitate graphical representation and statistical 
analysis, samples with no detectable ctDNA were given 
a value of 1 copy per ml. Control samples derived from 
plasma of age matched healthy individuals were used to 
determine the specificity of each assay (Supplementary 
Table 2). Most samples were tested only once against each 
mutation due to the limited amount of cfDNA available 
for analysis. We showed in a subset of 20 samples the 
reproducibility of the assay (Supplementary Figure 4).
Statistical analysis
PFS was defined as the time from the date of 
initiating therapy to the date of first reported PD or 
censored at the most recent visit. Baseline ctDNA was 
tested for association with overall response and 6-month 
PFS using one-sided Mann-Whitney U test. 
The ctDNA data was dichotomised in order to 
determine the best cut-off value to discriminate between 
groups of responders or non-responders, as well as those 
with PFS of more or less than 6 months (6mo PFS). 
Comparisons were performed using Fisher’s exact tests. 
The reported p-values have not been adjusted for multiple 
comparisons.
Univariate Cox proportional hazards regression 
Oncotarget42016www.impactjournals.com/oncotarget
analyses were performed to examine association of ctDNA 
levels, age, sex, metastatic disease stage and LDH status 
with PFS. Multivariate Cox regression models were 
evaluated using a stepwise approach with bidirectional 
elimination to determine the best fit model. Results were 
analysed in SPSS v22.0 and GraphPad Prism 5. Results 
were considered statistically significant at p < 0.05.
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